Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12867MR)

This product GTTS-WQ12867MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12867MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5044MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ12695MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ3027MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ13724MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ11567MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ5766MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ9978MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ1252MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW